This is a protocol preprint, a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Method Article
Flavie Sicard
OZ Biosciences
Corresponding Author
License:
This work is licensed under a CC BY-NC 3.0 License. Read Full License
In vivo Magnetofection has been developed for in vivo targeted transduction with any viral vectors (In vivo ViroMag). Virus/nanoparticles can be easily administrated through various injection routes such as systemic administration (intravenous, intra-artery) or local administration (intraperitoneal, intratumoral, intracerebroventricular, intramuscular).
Keywords
In Vivo, Transduction, AAV, lentivirus, retrovirus, adenovirus
Figure 1
Figure 2
Limited License for In vivo Magnetofection™
The purchase of In vivo Magnetofection™ Reagents grants the purchaser a non-transferable, non-exclusive license to use the kit and/or its separate and included components (as listed in section 1, Kit Contents). This reagent is intended for in-house research only by the buyer. Such use is limited to the transfection and transduction of nucleic acids and virus as described in the product manual. In addition, research only use means that this kit and all of its contents are excluded, without limitation, from resale, repackaging, or use for the making or selling of any commercial product or service without the written approval of OZ Biosciences.
Separate licenses are available from OZ Biosciences for the express purpose of non-research use or applications of In vivo Magnetofection™ Reagents. To inquire about such licenses, or to obtain authorization to transfer or use the enclosed material, contact the Director of Business Development at OZ Biosciences.
Buyers may end this License at any time by returning all In vivo Magnetofection™ Reagents material and documentation to OZ Biosciences, or by destroying In vivo Magnetofection™ Reagents components. Purchasers are advised to contact OZ Biosciences with the notification that In vivo Magnetofection™ Reagents kit is being returned in order to be reimbursed and/or to definitely terminate a license for internal research use only granted through the purchase of the kit(s).
This document covers entirely the terms of In vivo Magnetofection™ Reagents research only license, and does not grant any other express or implied license. The laws of the French Government shall govern the interpretation and enforcement of the terms of this License.
Product Use Limitations for In vivo Magnetofection™
In vivo Magnetofection™ Reagents and all of its components are developed, designed, intended, and sold for research use only. They are not to be used for human diagnostic or included/used in any drug intended for human use. All care and attention should be exercised in the use of the kit components by following proper research laboratory practices.
This is a list of supplementary files associated with this preprint. Click to download.
- supplement0.ppt
In vivo ViroMag – targeted viral infection icv Infection of rat embryo brain with adenovirus Sapet and coll. have shown that magnetic nanoparticles enhanced adenovirus transduction in vivo after intracerebroventricular injection (i.c.v.). Moreover, infection could be confined and directed towards the magnetic field. The uterine horns of pregnant rats [embryonic day 15] were exposed, and the third ventricle of each embryo was injected with Fast Green combined with Ad-GFP complexed to AdenoMag. When injected with AdenoMag, a magnet was applied for 30s following injection on one side of the embryo cranium. After injection, the uterine horns were replaced. Pictures show the third ventricle of E17 rat embryo (2 days post surgery). In brains non-exposed to magnet (A), the adenovirus-transduced cells are located on both side of the ventricle; cells are mainly restricted to this region indicating that the injection took place in this part of the brain. In brains exposed to magnetic field (B), the infected cells are located on one side of the ventricle due to the 30 s magnet-application represented by white arrow. From Sapet et al. Pharm Res 2011; (13).
- supplement0.ppt
In vivo ViroMag – targeted viral infection icv Infection of rat embryo brain with lentivirus ViroMag magnetic nanoparticles associated with lentivirus have been used by Sapet and coll. to concentrate and target viral transduction in rat brain. Results showed a significant enhancement of gene expression with Magnetofection™ than with standard infection. Brain sections at 8 days after lateral ventricular injection of 109 particles of GFP-lentivirus coupled with ViroMag into in utero rat embryos (E16) showed a diffuse GFP expression (in green) due to a widespread infection of neurons (A). The association of GFP-lentivirus with ViroMag induced a targeted local area as shown by the GFP expression in neurons lying under a magnet at the surface of the embryo skull (B). A more intense and restricted GFP-expression (C) was also observed when the magnet was positioned on the edge of the brain leading to an accumulation of viral particles and infected neurons in the focal area. From Sapet et al. ; Drug Delivery Technol., 201010:24-29 (14). The results present the high efficiency of In vivo ViroMag for targeted delivery of viral vector after intracerebroventricular injection
Loading...
Version History
CURRENT STATUS: Posted
Version 1
Posted 08 Jun, 2012
No community comments so far
Metrics
Comments: 0
HTML Views: ...
Method Article
Flavie Sicard
OZ Biosciences
Corresponding Author
Version History
CURRENT STATUS: Posted
Version 1
Posted 08 Jun, 2012
No community comments so far
Metrics
Comments: 0
HTML Views: ...
License:
This work is licensed under a CC BY-NC 3.0 License. Read Full License
In vivo Magnetofection has been developed for in vivo targeted transduction with any viral vectors (In vivo ViroMag). Virus/nanoparticles can be easily administrated through various injection routes such as systemic administration (intravenous, intra-artery) or local administration (intraperitoneal, intratumoral, intracerebroventricular, intramuscular).
Figure 1
Figure 2
Loading...